Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a

Jakesz, R.; Greil, Richard; Gnant, Michael; Schmid, Marianne; Kwasny, Werner; Kubista, E.; Mlineritsch, Brigitte; Tausch, Christoph; Stierer, M.; Hofbauer, F; Renner, Karl; Dadak, Christian; Rücklinger, Ernst; Samonigg, Hellmut

doi:10.1093/jnci/djm246

Cited by 282 publications

(132 citation statements)

References 21 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…To reduce the risk of late recurrence and death (i.e., 5-10 years after diagnosis, or even later), several trials of extending endocrine therapy after 5 years of tamoxifen have been reported thus far (3)(4)(5)(6)(7). The results of these trials suggest that extended endocrine treatment can reduce recurrence and breast cancer mortality during the second decade after diagnosis.…”

Section: Introductionmentioning

confidence: 99%

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Filipits¹,

Nielsen

Rudas

et al. 2014

Clinical Cancer Research

182

View full text Add to dashboard Cite

Purpose: To assess the prognostic value of the PAM50 risk-of-recurrence (ROR) score on late distant recurrence (beyond 5 years after diagnosis and treatment) in a large cohort of postmenopausal, endocrineresponsive breast cancer patients.Experimental Design: The PAM50 assay was performed on formalin-fixed paraffin-embedded wholetumor sections of patients who had been enrolled in the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-8). RNA expression levels of the PAM50 genes were determined centrally using the nCounter Dx Analysis System. Late distant recurrence-free survival (DRFS) was analyzed using Cox models adjusted for clinical and pathologic parameters.Results: PAM50 analysis was successfully performed in 1,246 ABCSG-8 patients. PAM50 ROR score and ROR-based risk groups provided significant additional prognostic information with respect to late DRFS compared with a combined score of clinical factors alone (ROR score: DLRc 2 15.32, P < 0.001; ROR-based risk groups: DLRc 2 14.83, P < 0.001). Between years 5 and 15, we observed an absolute risk of distant recurrence of 2.4% in the low ROR-based risk group, as compared with 17.5% in the high ROR-based risk group. The DRFS differences according to the PAM50 ROR score were observed for both node-positive and node-negative disease. Conclusion: PAM50 ROR score and ROR-based risk groups can differentiate patients with breast cancer with respect to their risk for late distant recurrence beyond what can be achieved with established clinicopathologic risk factors. Clin Cancer Res; 20(5); 1298-305. Ó2014 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Filipits¹,

Nielsen

Rudas

et al. 2014

Clinical Cancer Research

182

View full text Add to dashboard Cite

show abstract

“…234 At a median followup of 62.3 months, women who received anastrozole (n=387) were reported to have a statistically significantly reduced risk of recurrence compared with women who received no further treatment (n=469; HR, 0.62; 95% CI, 0.40-0.96; P=.031). 234 The differences in design and patient populations among the studies of aromatase inhibitors do not allow for the direct comparison of the results of these studies. A meta-analysis of adjuvant trials of aromatase inhibitors versus tamoxifen alone versus after 2 or 3 years of tamoxifen documented lower recurrence rates with the aromatase inhibitor-containing regimen, with no clear impact on overall survival.…”

mentioning

confidence: 97%

Breast Cancer Version 3.2014

Gradishar¹,

Anderson²,

Blair³

et al. 2014

J Natl Compr Canc Netw

172

116

View full text Add to dashboard Cite

“…In particular, there was a nine fold increase in the rate of carpal tunnel syndrome for those receiving the AI. This study also reported symptoms after treatment cessation and [94] showed rates of arthralgia of 20.8% and 15.1% for both exemestane and tamoxifen, respectively [7,8]. QoL analysis using the FACT-B TOI showed no meaningful change between the two study groups [51].…”

Section: Switch Therapymentioning

confidence: 67%

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

Din

Dodwell

Wakefield

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Aromatase inhibitors (AIs) are a standard of care for the adjuvant treatment of hormone responsive early carcinoma of the breast as demonstrated in a number of large international phase III randomised trials. Arthralgia was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice. Although rates of up 35% have been reported in the randomised trials, the figure has been much higher in subsequent case series. There is concern that these symptoms are significant and may affect compliance and thus the overall efficacy of treatment. It is therefore extremely important that we evaluate this syndrome with a view to gaining more information regarding its clinical features and possible aetiological mechanism. The potential aetiological mechanisms and evidence for aromatase inhibitor-induced arthralgia (AIA) are reviewed in this article. Looking forward, it is now important that prospective clinical trials are well designed to evaluate this syndrome and potential therapeutic strategies to circumvent it. Radiological imaging and biochemical analyses may help our understanding of AIA and these are discussed.

show abstract

Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a

Cited by 282 publications

References 21 publications

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Breast Cancer Version 3.2014

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

Contact Info

Product

Resources

About